ライフサイエンスコーパス: renal disease

1 diagnosed in 56 patients (17 with end-stage renal disease).

2 disease (SCI-Diabetes: 62 years; 35% cardio-renal disease).

3 sation for heart failure, and progression of renal disease.

4 patients with type 1 diabetes and end stage renal disease.

5 ncreasing albuminuria and the progression of renal disease.

6 1, onwards along with the specified cause of renal disease.

7 ction mutations contribute to cardiac and/or renal disease.

8 a requisite for the development of end-stage renal disease.

9 s and the leading genetic cause of end-stage renal disease.

10 (DN) remains the leading cause of end-stage renal disease.

11 erse outcomes compared with patients without renal disease.

12 nd, thus, can prevent progression to chronic renal disease.

13 eloped a TMA due to CD and reached end-stage renal disease.

14 tion, end-stage liver disease, and end-stage renal disease.

15 osis, a condition that can lead to end-stage renal disease.

16 ne glycol poisoning, can result in end-stage renal disease.

17 lated hospitalization or death, or end-stage renal disease.

18 s, with inescapable progression to end-stage renal disease.

19 urce of diagnostic and prognostic markers of renal disease.

20 is an indicator of microvascular damage and renal disease.

21 ove care and retard progression to end-stage renal disease.

22 filtration rate via Modification of Diet in Renal Disease.

23 ority of patients who undergo MitraClip have renal disease.

24 ive uropathy (OR, 12.4; P < 0.01) as primary renal disease.

25 associated with a 10-year risk of end-stage renal disease.

26 not be applicable for patients with eye and renal disease.

27 erpretation of urine protein measurements in renal disease.

28 reatment to prevent progression to end-stage renal disease.

29 knowledged as the best therapy for end-stage renal disease.

30 tial fibrosis, eventually leading to chronic renal disease.

31 ependent contributions of these disorders to renal disease.

32 uced risk of future progression to end-stage renal disease.

33 T2 inhibition in the progression of diabetic renal disease.

34 ients, including patients with non-end-stage renal disease.

35 proof of causality of these risk alleles for renal disease.

36 e perspective of chronic cardiometabolic and renal disease.

37 receptors in causing pain during diabetes or renal disease.

38 , ICU stay less than 24 hours, and end-stage renal disease.

39 ary disease, peripheral vascular disease, or renal disease.

40 ferred treatment for patients with end-stage renal disease.

41 ill enable improvements in MSC therapies for renal disease.

42 enesis, has been suggested as a biomarker of renal disease.

43 , eGFR decline of 30% or more, and end-stage renal disease.

44 el, end-stage renal disease, or death due to renal disease.

45 kidney disease, eGFR decline, and end-stage renal disease.

46 nterval, 1.82-2.12) in people without cardio-renal disease.

47 s) of induction and the role of periostin in renal disease.

48 n is a lifesaving intervention for end-stage renal disease.

49 is is associated with cancer progression and renal disease.

50 L users in order to delay the progression of renal disease.

51 ider continuity, for patients with end-stage renal disease.

52 serum hsCRP levels in adults with end-stage renal disease.

53 e likely to vary depending on the underlying renal disease.

54 tioning of the kidneys, leading to end-stage renal disease.

55 heart failure hospitalization and end-stage renal disease.

56 modifying medications than those with cardio-renal disease.

57 physiology and spectrum of Fontan-associated renal disease.

58 use of senotherapeutics in the management of renal disease.

59 high blood levels in patients with advanced renal diseases.

60 co-existing form of heart failure (HF) with renal diseases.

61 f MYOCD in the DCM patients with and without renal diseases.

62 s new drug targets to treat APOL1-associated renal diseases.

63 t alleles are at elevated risk of developing renal diseases.

64 rogression of immune- and nonimmune-mediated renal diseases.

65 es of these genes in kidney cell biology and renal diseases.

66 TGF-beta signaling, including biomarkers of renal diseases.

67 tions, and tissue repair and regeneration in renal diseases.

68 erly, especially among persons with existing renal diseases.

69 ecules was shown to be promising in treating renal diseases.

70 The most common grouped causes of death were renal disease (102, 23.4%), neoplasia (37, 8.5%) and mas

71 d categories, including congenital or cystic renal disease (127 of 531 patients [23.9%]) and nephropa

72 for >=90 d using the modification of diet in renal disease-4 equation).

73 ared with 1.5%; p = 0.0041), and preexisting renal disease (9.1% compared with 3.0%; p < 0.0001) had

74 rtality as well as increased risk of chronic renal disease, a finding that is especially relevant amo

75 In contrast to chronic renal disease, acute injury may be repaired, a process t

76 erapeutic option for patients with end-stage renal disease after orthotopic liver transplantation (OL

77 ipoprotein cholesterol levels, hypertension, renal disease, age, and sex.

78 me to the first occurrence of cardiovascular-renal diseases, all-site cancer, and/or death, based on

79 rimposed upon clinical cardiovascular and/or renal disease, alone or as part of a systemic disorder.

80 Given increased risk for end-stage renal disease among obese living donors, center-level ef

81 Secondary outcomes were end-stage renal disease and acute kidney injury.

82 Patients with end-stage renal disease and aortoiliac stenosis are often consider

83 lence rates of diabetes mellitus and chronic renal disease and are more likely to present with gangre

84 including pre-existing comorbidities such as renal disease and cardiovascular disease (CVD).

85 omyopathy that was associated with end-stage renal disease and characterized by severe functional abn

86 ohorts of patients with suspected hereditary renal disease and chronic proteinuria.

87 Both modification of diet in renal disease and Cockcroft-Gault equations displayed th

88 the leading cause of blindness and end-stage renal disease and contributes to both microvascular and

89 ogic assays characterize the presentation of renal disease and enable useful pharmacologic interventi

90 oke, associations between retinal emboli and renal disease and function remain unclear.

91 pment and progression of cardiometabolic and renal disease and is associated with increased cardiovas

92 airment is common in patients with end-stage renal disease and is associated with poor outcomes on di

93 donation are at increased risk of end-stage renal disease and may benefit from intensive postdonatio

94 is with unusual systemic features, including renal disease and platelet dysfunction, caused by the de

95 al immunoglobulin (MIg) in the occurrence of renal disease and raises the issue of the therapeutic ma

96 resenting up to 30% of patients in end-stage renal disease and renal transplantation, is the main ind

97 ine new light on the pathogenesis of various renal diseases and provide a basis for further hypothesi

98 significantly more likely to have diabetes, renal disease, and chronic pulmonary disease and had sig

99 atheters, diabetes mellitus, AIDS, end-stage renal disease, and cirrhosis), need for intensive care,

100 aboration (CKD-EPI), Modification of Diet in Renal Disease, and Cockcroft-Gault equations, and we eva

101 nce of diabetes, prior stroke, hypertension, renal disease, and congestive heart failure than white m

102 ary artery disease, heart failure, end-stage renal disease, and dementia.

103 ey injury, chronic kidney disease, end-stage renal disease, and electrolyte abnormalities.

104 ary endothelial dysfunction, liver fibrosis, renal disease, and exercise intolerance are common in ad

105 as Cockcroft-Gault, Modification of Diet in Renal Disease, and Jelliffe's.

106 analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained indepe

107 involved in the pathogenesis of cardiac and renal diseases, and in the progression of tumour growth

108 ies (cardiovascular, respiratory, liver, and renal diseases, and non-AIDS defining cancers because of

109 , and assess relevant risk factors including renal disease, antiphospholipid antibody, and anti-Ro/SS

110 re (adjusted odds ratio [aOR] 1.38), chronic renal disease (aOR 1.19), age >85 years (aOR 1.17), prio

111 reatment options for patients with end-stage renal disease are being sought.

112 on and depletion as novel therapies to treat renal disease are discussed, and we explore unanswered q

113 arch, therapeutic options to halt or reverse renal disease are rather limited.

114 , the mechanisms underlying APOL1-associated renal diseases are unknown.

115 Competing risk factors for renal disease (arterial hypertension, fat metabolism dis

116 of systemic lupus erythematosus (SLE), using renal disease as a proxy for severity.

117 ts to identify subjects at risk of end-stage renal disease, as well as biomarkers to measure response

118 Nine patients (42%) had end stage renal disease at a mean age of 10.6 years (6.5-17 years)

119 erate personalized in vivo models of genetic renal diseases bearing patient-specific mutations.

120 me in models of stress urinary incontinence, renal disease, bladder dysfunction and erectile dysfunct

121 e interval, 1.01-1.17) in people with cardio-renal disease but 1.96 (95% confidence interval, 1.82-2.

122 undergoing peritoneal dialysis for end-stage renal disease but without cirrhosis were included as con

123 rsus NHWs) in the first year after end-stage renal disease, but by Year 4, access to transplantation

124 SGLT2i reduced the risk of progression of renal disease by 45% (0.55 [0.48-0.64], p<0.0001), with

125 ey disease (ADPKD) is an inherited monogenic renal disease characterised by the accumulation of clust

126 R2 transgenic mice exhibited signs of severe renal disease characteristic of FSGS with proteinuria, l

127 Background Glomerulonephritis refers to renal diseases characterized by glomerular and tubuloint

128 isease (ADPKD) is the most common hereditary renal disease, characterized by cyst formation and growt

129 mic underlying diseases, including end-stage renal disease, cholestatic liver disease, endocrine/meta

130 Chronic renal disease (CKD) jeopardizes the long-term outcomes o

131 itus or peripheral vascular disease, primary renal disease classification, and angiotensin converting

132 hich has been observed in the progression of renal disease, contributes to GN progression.

133 from 2.4 to 3.8, p <0.05) included end-stage renal disease, coronary artery disease, and neurologic d

134 cardiovascular disease, end-stage liver and renal disease, death) was compared between regimens usin

135 less than 60 mL/min per 1.73m(2), end-stage renal disease (defined as dialysis for at least 90 days,

136 he inflammatory process underlying end-stage renal disease development in both types of diabetes.

137 ablish a connection between sex hormones and renal disease development or progression, development of

138 ched for age, body mass index, hypertension, renal disease, diabetes mellitus, and AS severity.

139 nce of African American ethnicity, end-stage renal disease, diabetes, fair/poor self-rated health, ph

140 ublic insurance or no insurance at end-stage renal disease diagnosis, more regional acute care hospit

141 The spectrum of biopsy proven renal diseases differs between locations and changes ove

142 ute myocardial infarction, stroke, end-stage renal diseases, end-stage liver diseases, or death.

143 s most commonly caused by genetic disorders, renal disease, endocrine disorders, or cardiovascular ab

144 rbate azotemia, increase clinical markers of renal disease, enhance glomerular immune complex deposit

145 on rate based on the Modification of Diet in Renal Disease equation (119.5 +/- 57.2 vs 93.0.0 +/- 32.

146 on rate based on the Modification of Diet in Renal Disease equation (147.9 +/- 50.2 vs 126.0 +/- 41.9

147 calculated using the Modification of Diet in Renal Disease equation.

148 The CKD-EPI and Modification of Diet in Renal Disease equations demonstrated strong agreement, p

149 a link between apical polarity proteins and renal diseases, especially renal cyst diseases.

150 ng donors who subsequently develop end-stage renal disease (ESRD) also have higher graft failure, sug

151 endent predictor of posttransplant end-stage renal disease (ESRD) and mortality.

152 Patients with end-stage renal disease (ESRD) are characterized by increased card

153 erative processes in patients with end-stage renal disease (ESRD) compared to healthy controls.

154 Patients with end-stage renal disease (ESRD) due to lupus nephritis (LN) have hi

155 on between serum 1,5-AG levels and end-stage renal disease (ESRD) from baseline (1990-1992) through 2

156 00 people and slowly progresses to end-stage renal disease (ESRD) in about half of these individuals.

157 he chronic kidney disease (CKD) or end stage renal disease (ESRD) is generally caused due to the prog

158 6500 undocumented immigrants with end-stage renal disease (ESRD) live in the United States.

159 ine in eGFR (1.23, 1.15-1.33), and end-stage renal disease (ESRD) or >=50% decline in eGFR (1.17, 1.0

160 ing sociocultural factors preclude end-stage renal disease (ESRD) patients from initiating kidney tra

161 ant is the best treatment for most end-stage renal disease (ESRD) patients, but proportionally few ES

162 atitis C virus (HCV) infection and end-stage renal disease (ESRD) remains controversial without consi

163 ort studies that generate lifetime end-stage renal disease (ESRD) risks for young living kidney donor

164 sthma, diabetes mellitus (DM), and end-stage renal disease (ESRD) were calculated by Poisson regressi

165 Participants with end-stage renal disease (ESRD) were excluded.

166 ons are important complications of end-stage renal disease (ESRD) with few studies having investigate

167 ts with CKD, especially those with end-stage renal disease (ESRD), are controversial.

168 sease (CKD) to predict the risk of end stage renal disease (ESRD), i.e., the need for dialysis or a k

169 , 5%, and 8% of patients developed end-stage renal disease (ESRD), major cardiovascular event (mCVE),

170 In patients with end-stage renal disease (ESRD), surgical aortic valve replacement

171 te the association between HCM and end-stage renal disease (ESRD).

172 g longer, and 11%-18% will develop end stage renal disease (ESRD).

173 patient with multiple myeloma and end-stage renal disease (ESRD).

174 was associated with development of end-stage renal disease (ESRD).

175 on (AF) is common in patients with end-stage renal disease (ESRD).

176 surface area (PISA) in adults with end-stage renal disease (ESRD).

177 were strongly associated with cardiovascular/renal disease events and all-cause mortality (p < 0.0001

178 ubsequent fatal and non-fatal cardiovascular/renal disease events in AA subjects.

179 ease events, and 255 of 35 620 had end-stage renal disease events), about 17% were older than 50 year

180 e subsequent incidence of cardiovascular and renal disease events, follow-up information was obtained

181 added value as a predictor of cardiovascular/renal disease events.

182 ne or more fatal or non-fatal cardiovascular/renal disease events.

183 ll nephropathy as primary cause of end-stage renal disease), for a liver transplant 14.3 (recipient s

184 were assessed by the Modification of Diet in Renal Disease formula (MDRD-4) up to 5 years after LT.

185 calculated using the Modification of Diet in Renal Disease formula.

186 Renal disease further modifies these patterns.

187 ETHODSWe used next-generation sequencing for renal disease genes to genotype cohorts of patients with

188 Children with renal disease had highly variable and often markedly ske

189 ication for replacement therapy in end-stage renal disease have been widely discussed.

190 osis, non-alcoholic steatohepatitis, chronic renal disease, heart failure, diabetes, idiopathic pulmo

191 e-sensitive populations, including end-stage renal disease, heart failure, obesity, advanced age, or

192 tcome analyses controlled for sex, end-stage renal disease, heart failure, sepsis severity (severe se

193 cipients' age, cause and length of end-stage renal disease, hemoglobin, albumin, selected comorbiditi

194 th older age, lower body mass index, chronic renal disease, higher Sequential Organ Failure Assessmen

195 t predictors of MACE were cardiogenic shock, renal disease, history of peripheral vascular disease, m

196 on, cancer hospital admission, and end-stage renal disease hospital admission) were identified.

197 hown to independently predict progression of renal disease, however, whether FGF23 and FGFR4 also con

198 lso associated with development of end-stage renal disease (HR, 2.40; 95% CI, 0.76-7.58) and acute ki

199 al {CI}, 1.48-9.92]; P = .004) and end-stage renal disease (HR, 4.27 [95% CI, 1.89-9.11]; P = .001) w

200 A common renal disease, immunoglobulin A (IgA) nephropathy (IgAN)

201 Renal diseases impose considerable health and economic b

202 the largest reported cohort of patients with renal disease in Bardet-Biedl syndrome and identifies ri

203 n chronic hyperoxaluria, promoting end-stage renal disease in children and young adults.

204 be involved in the development of end-stage renal disease in diabetes, but which specific circulatin

205 D) constitutes the fourth cause of end-stage renal disease in Europe.

206 longer survival, the prevalence of end-stage renal disease in HIV is increasing.

207 s the previously underestimated relevance of renal disease in HPS.

208 ted expression of APOL1-G1 could precipitate renal disease in humans.

209 wo clusters of proteins were associated with renal disease in lupus nephritis samples.

210 he GRS performed better in the prediction of renal disease in the 'later onset' compared with the 'ea

211 he most common cause of hereditary end-stage renal disease in the first three decades of life.

212 e substantially ameliorates autoimmunity and renal disease in the MRL/lpr model of SLE.

213 icant positive correlation between a GRS and renal disease in two independent European GWAS (Pcohort1

214 role of uric acid (UA) in the development of renal disease, in which endothelial dysfunction is regar

215 ysate temperature in patients with end-stage renal disease is associated with a decrease in the frequ

216 Preprocedural renal disease is associated with poor outcomes, particul

217 Renal disease is associated with poor prognosis despite

218 Patient survival with end-stage renal disease is longer after kidney transplantation (KT

219 ic kidney disease progression, and end-stage renal disease is not clear.

220 ase in the number of patients with end-stage renal disease leads to a growing waiting list for kidney

221 to lupus nephritis (LN)-associated end-stage renal disease (LN-ESRD) in African Americans.

222 s mainly seen, a limited form (i.e., with no renal disease) may also occur.

223 llow-up visit in the Modification of Diet in Renal Disease (MDRD) Study from 482 participants in stud

224 nsion (AASK) and 761 Modification of Diet in Renal Disease (MDRD) Trial participants previously rando

225 participants in the Modification of Diet in Renal Disease (MDRD) trial.

226 ration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD-4, MDRD-6) equations for mGFR < 30 m

227 v) scores, renal function, and the burden of renal disease measured by area under the curve (serum cr

228 Monoclonal immunoglobulin (MIg) associated renal disease (MIgARD) comprises a group of disorders ca

229 Monoclonal immunoglobulin (MIg)-associated renal disease (MIgARD) comprises a group of disorders ca

230 We also show its applicability for renal disease modeling and drug testing.

231 iff-stained kidneys from various species and renal disease models.

232 etes and to assess if the presence of cardio-renal disease modifies these relationships.

233 for potential drug repurposing, as baseline renal disease must be considered when selecting medicati

234 icians involved in the care of patients with renal disease must be familiar with the local epidemiolo

235 of creatinine > 75 mL/min) patients with no renal disease (n = 24); Group 2 (clearance of creatinine

236 of creatinine of 11-75 mL/min) patients with renal disease (n = 67); Group 3 (clearance of creatinine

237 pairment and Imaging Correlates in End Stage Renal Disease, NCT01883349.

238 ations, otherwise known as nail patella-like renal disease (NPLRD).

239 d spectrum of BBS phenotypes spans diabetes, renal disease, obesity, sleep apnea, cardiovascular dise

240 s for severe infection included pre-existing renal disease (odds ratio [OR], 7.4; 95% CI, 2.5-22.0),

241 tio, 0.18; CI, 0.13-0.25), or with end-stage renal disease (odds ratio, 0.23; CI, 0.13-0.40), heart f

242 nsion (odds ratio, 2.6; 95% CI, 1.2-5.6) and renal disease (odds ratio, 3.5; 95% CI, 1.9-6.5) were as

243 Patients with end-stage renal disease on hemodialysis (ESRD-HD) and aortic steno

244 the human study, participants with end-stage renal disease on peritoneal dialysis (PD) underwent rand

245 NHBs and Year 4 in Hispanics after end-stage renal disease onset.

246 the majority of patients reaching end-stage renal disease or dying with little or no chances of kidn

247 The risk of end-stage renal disease or renal death was lower in the dapagliflo

248 ease (OR 2.62; 95% CI 1.53-4.47; p < 0.001), renal disease (OR 2.13; 95% CI 1.84-2.46; p < 0.001), an

249 ing of the serum creatinine level, end-stage renal disease, or death due to renal disease.

250 glomerular filtration rate (eGFR), end-stage renal disease, or death from renal causes), the individu

251 associated with excess mortality, end-stage renal disease, or morbidity, in at least 10 years follow

252 tion, end-stage liver disease, and end-stage renal disease outcomes that could be prevented with inte

253 ction, end-stage liver disease, or end-stage renal disease outcomes.

254 tion, end-stage liver disease, and end-stage renal disease outcomes.

255 073) and lesser reductions in progression of renal disease (p for interaction=0.0258) in patients wit

256 l antibody tesidolumab (LFG316) in end-stage renal disease patients awaiting kidney transplant.

257 stereology, with a possible application for renal disease patients who are often not suitable for co

258 be used to treat thyroid cancer in end-stage renal disease patients who undergo hemodialysis.

259 iving-donor kidney transplants for end-stage renal disease patients with willing but incompatible liv

260 ted research has been conducted on end-stage renal disease patients.

261 During the end-stage renal disease phase at the time of transplant, cinacalce

262 ors of major adverse cardiac events included renal disease, prior myocardial infarction, silent ische

263 er elevated suPAR levels are associated with renal disease progression in children with CKD.

264 Tissue fibrosis is an important index of renal disease progression.

265 plications of LPI, including growth failure, renal disease, pulmonary alveolar proteinosis, autoimmun

266 plant recipients with aHUS-related end-stage renal disease received eculizumab: 10 from day 0 and 2 a

267 isation for heart failure and progression of renal disease regardless of existing atherosclerotic car

268 e, yet the evidence for its association with renal disease remains underrecognized.

269 ase, doubling of serum creatinine, end-stage renal disease, renal transplant, or renal death.

270 ng, type II diabetes mellitus, and end-stage renal disease requiring dialysis presented to the emerge

271 ng, type II diabetes mellitus, and end-stage renal disease requiring dialysis presented to the emerge

272 e age in T2D was 63 years and 28% had cardio-renal disease (SCI-Diabetes: 62 years; 35% cardio-renal

273 A 50-year-old woman with end-stage renal disease secondary to autosomal dominant polycystic

274 n-infantile disease (11%, all with end-stage renal disease) showed mild, likely PH1-related retinal f

275 d in a striking acceleration in the onset of renal disease, SLO germinal center formation, and autore

276 ents with both type 1 diabetes and end-stage renal disease, SPK recipients had similar progression of

277 ional ISAR (Risk Stratification in End-Stage Renal Disease) study, data on dynamic retinal vessel ana

278 ng System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or pro

279 ay substantially reduce risk for cardiac and renal disease, suggesting that it may be necessary to ch

280 Acute or pre-existing renal disease, supplemental oxygen upon hospitalization,

281 at higher risk for progression to end-stage renal disease than those who have chronic kidney disease

282 AKUT as a feature (syndromic CAKUT) or cause renal diseases that may manifest as phenocopies of CAKUT

283 For renal disease, the PAF was greatest for hypertension (39

284 than 65 years of age), such as in end-stage renal disease, this therapy has not been optimized for o

285 In patients with end-stage renal disease undergoing hemodialysis, it was recently s

286 Patients with end-stage renal disease use the emergency department (ED) at a 6-f

287 In up to 15 years, follow-up end-stage renal disease was observed in 1 LD versus 7 THIN (P = 0.

288 n immunodeficiency virus (HIV) and end-stage renal disease was on the kidney transplant waitlist awai

289 rious associations of lymphangiogenesis with renal disease, we here tested the hypothesis that VitD h

290 rlying cardiovascular disease, diabetes, and renal disease were significantly associated with higher

291 People without cardio-renal disease were younger and more likely to have likel

292 poor outcomes, particularly in stage 4 or 5 renal disease where 1-year mortality is observed in near

293 APOL1 was strongly associated with incident renal disease, whereas no significant association with t

294 agonist anti-Ox40 mAbs potently exacerbated renal disease, which was accompanied by activation of ki

295 Patients with end-stage renal disease who are undergoing dialysis are reported t

296 gn on 29,095 elderly patients with end-stage renal disease who died between 2005 and 2013.

297 y disease, particularly those with end-stage renal disease who require dialysis and/or kidney transpl

298 ection represents a unique RNA virus-induced renal disease with significant proteinuria.

299 y donors have an increased risk of end-stage renal disease, with hypertension and diabetes as the pre

300 People with T2D without cardio-renal disease would be predicted to benefit greatly from